Circle Pharma, a spinout of UCSF and UC Santa Cruz, has collected series B funding from investors including another UC campus, Berkeley.
Circle Pharma, a US-based oncology therapeutics spinout of University of California (UC), San Francisco and Santa Cruz, secured $45m on Tuesday in a series B round backed by UC Berkeley’s investment vehicle, Berkeley Catalyst Fund.
Healthcare-focused venture capital fund Column Group led the round, which also included pharmaceutical firm ShangPharma, Nextech Invest and LifeForce Capital.
Circle is developing cancer drugs that are formed around strings of amino acids called peptides which make up structures called macrocycles. It represents…
